ArticleFrontiers in cellular and infection microbiology2025
Synergistic antibacterial effects of postbiotics combined with linezolid and amikacin against nosocomial pathogens.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Probiotic-Derived Antimicrobial Proteins and Peptides: Molecular Mechanisms, Clinical Applications, and Future Therapeutic Perspectives.Probiotics and antimicrobial proteins · 2026Review
- Postbiotics as Multifunctional Bioactives: Mechanistic Insights and Translational Applications in Host Physiology and Microbial Ecosystem Modulation.Microorganisms · 2026Review
- Yeast-Derived Postbiotics for Prevention of Enteric Diseases in Farm Animals: Current Insights and Future Perspectives.Veterinary sciences · 2026Review
- Microbiotherapy: an emerging adjunct for burn wound healing.Frontiers in cellular and infection microbiology · 2026Review
- Postbiotic Effects ofMicroorganisms · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: The global rise in antimicrobial resistance (AMR) has rendered many conventional antibiotics less effective, particularly against nosocomial pathogens such as Materials and methods: Postbiotics were obtained through anaerobic fermentation, followed by centrifugation and filtration. Cytotoxicity was assessed via MTT assays on Vero cell lines. Infection models involving pathogen-specific adhesion and invasion assays were used, with CFU/mL quantification and statistical evaluation by one-way ANOVA and Tukey's Results: The postbiotics exhibited potent antimicrobial activity across all tested pathogens. Combined with linezolid, the dual and triple postbiotic formulations significantly enhanced antibacterial effects against Conclusions: In conclusion, postbiotic-antibiotic combinations, especially with linezolid and amikacin, present promising low-toxicity, synergistic therapeutic strategies. These results lay a strong foundation for advancing microbiome-based adjunct therapies to combat AMR in clinical settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.